Analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.
Separately, Cantor Fitzgerald reissued a “neutral” rating and set a $3.30 price target on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.
Read Our Latest Stock Report on Aspira Women’s Health
Aspira Women’s Health Price Performance
Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last posted its earnings results on Tuesday, May 21st. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The firm had revenue of $2.15 million during the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the prior year, the business earned ($10.94) EPS. On average, research analysts expect that Aspira Women’s Health will post -1.3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aspira Women’s Health
An institutional investor recently raised its position in Aspira Women’s Health stock. Quantum Private Wealth LLC raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 76.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,156 shares of the company’s stock after purchasing an additional 21,788 shares during the quarter. Quantum Private Wealth LLC owned about 0.49% of Aspira Women’s Health worth $205,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 12.19% of the company’s stock.
Aspira Women’s Health Company Profile
Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
Further Reading
- Five stocks we like better than Aspira Women’s Health
- Investing In Preferred Stock vs. Common Stock
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Golden Cross Stocks: Pattern, Examples and Charts
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Why Invest in High-Yield Dividend Stocks?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.